Joanne Kotsopoulos, PhD, from Women's College Research Institute in Toronto, Canada, discusses the complex topic of how hormones, including oral contraceptives, hormone replacement therapy, and anti-hormones like tamoxifen, may impact the risk of breast cancer in women with BRCA1 or BRCA2 mutations. As these individuals face high risks of breast and ovarian cancer, managing cancer risks while considering adverse outcomes from surgical prevention is crucial. Women with BRCA mutations often undergo preventive surgeries, and understanding the safety of hormone use, especially post-surgery, is essential. Dr Kotsopoulos emphasizes the need for clarity to guide clinicians and patients in making informed decisions. This interview occurred at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
